{"documentId":"1O8CongressCalendar2026_qrs109TuVwXyZ12AbCdEfGhI","title":"2026 Congress Calendar & Coverage Plan","revisionId":"rev-1O8CongressC","body":{"content":[{"sectionBreak":{"sectionStyle":{"columnSeparatorStyle":"NONE","contentDirection":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":40,"textRun":{"content":"2026 Congress Calendar & Coverage Plan\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"TITLE","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":116,"textRun":{"content":"Prepared by Medical Communications. Distribution: Medical Affairs leadership, VP Commercial, MSL Lead, CI Analyst.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":10,"textRun":{"content":"Overview\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":339,"textRun":{"content":"This document captures the 2026 congress coverage plan for Zenvara/Veltarix, including priority meetings, accepted abstracts, sponsored symposia, and the CI/MSL coverage strategy. The plan reflects 14 abstracts accepted across the four priority congresses (ASCO, ESMO, AHA, ACR), with sponsored symposium slots confirmed at ESMO and ACR.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":30,"textRun":{"content":"Priority congresses (Tier 1)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":298,"textRun":{"content":"ASCO Annual Meeting — June 5-9, 2026, Chicago, IL. Primary audience: US oncology. Our presence: 4 abstracts (1 LBA at Plenary, 2 oral, 1 poster). Symposium: pending — meeting space confirmed but session content under review. MSL field coverage: full team. CI coverage: Jordan + 2 backup analysts.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":360,"textRun":{"content":"ESMO Congress — September 12-16, 2026, Madrid. Primary audience: European oncology. Our presence: 5 abstracts (1 oral, 2 poster discussions, 2 posters). Symposium: confirmed, Tuesday September 15 evening slot, title: 'Long-term durability outcomes in PD-L1-high NSCLC: implications for first-line treatment.' MSL field coverage: full team plus regional MSLs.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":230,"textRun":{"content":"AHA Scientific Sessions — November 7-10, 2026, New Orleans. Primary audience: cardiology (interest in checkpoint inhibitor cardiotoxicity profile). Our presence: 1 poster on cardiovascular safety in long-term ZENITH-1 follow-up.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":189,"textRun":{"content":"ACR Annual Meeting — November 14-18, 2026, Washington DC. Primary audience: rheumatology (immune-related AE management). Our presence: 1 poster + 1 symposium on irAE management protocols.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":52,"textRun":{"content":"Secondary congresses (Tier 2 — selective coverage)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":198,"textRun":{"content":"ELCC (European Lung Cancer Congress) — March 12-15, 2026, Copenhagen. Reviewed: completed. Veltarix data: interim ZENITH-1 European subgroup analysis presented. No new abstracts targeted for 2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":130,"textRun":{"content":"WCLC (World Conference on Lung Cancer) — September 5-8, 2026, Boston. Adjacent timing to ESMO; selected oral abstract slot only.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":104,"textRun":{"content":"AACR Annual Meeting — April 25-30, 2026, Atlanta. Reviewed: completed. Translational research updates.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":123,"textRun":{"content":"AMCP Nexus — October 13-15, 2026, Boston. Market access focused. AMCP Format for Formulary Submissions dossier presented.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":32,"textRun":{"content":"Accepted abstracts — ASCO 2026\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":310,"textRun":{"content":"Abstract LBA — ZENITH-1 5-year OS update. Presented at Plenary Session, Sunday June 7 morning. Embargo lifts June 7. PI presenter: Dr. Mok. Co-authors: Peters, Schmid, Rizvi, Ramalingam, Mok. Implications: 5-year OS data is the durability proof point for the franchise and for HTA submissions in development.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":212,"textRun":{"content":"Abstract 9001 — ZENITH-1 PD-L1 subgroup analysis (TPS 50-79% vs 80%+). Oral Abstract Session, Lung Cancer Non-Small Cell Metastatic track. Tuesday June 9 morning. Presenter: Dr. Mok. Closes NICE evidence gap 3.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":170,"textRun":{"content":"Abstract 9002 — Real-world effectiveness from Optum claims cohort. Oral Abstract Session, same track. Tuesday June 9 morning. Presenter: Sara Lindqvist (HEOR Director).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":148,"textRun":{"content":"Abstract 9501 — Patient-reported outcomes (EQ-5D-5L, EORTC QLQ-LC13) from ZENITH-1. Poster Session, Sunday June 7. Presenter: PRO co-investigator.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":32,"textRun":{"content":"Accepted abstracts — ESMO 2026\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":96,"textRun":{"content":"Oral Abstract — ZENITH-1 24-month survival update with subgroup analysis. Oral Session, NSCLC.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":83,"textRun":{"content":"Poster Discussion — ITC vs platinum doublet, methodology comparison. NMA section.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":67,"textRun":{"content":"Poster Discussion — Cost-effectiveness analysis (UK perspective).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":92,"textRun":{"content":"Poster — Real-world effectiveness from European cohort (Italian SIO + French AMIROS data).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":68,"textRun":{"content":"Poster — Treatment patterns and sequencing in 1L PD-L1-high NSCLC.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":19,"textRun":{"content":"Symposium content\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":357,"textRun":{"content":"ESMO symposium (Sep 15 evening): 'Long-term durability outcomes in PD-L1-high NSCLC: implications for first-line treatment.' Three speakers: Dr. Peters (overview of the long-term durability question), Dr. Mok (ZENITH-1 5-year data), Dr. Schmid (clinical interpretation and positioning). Followed by panel discussion with audience Q&A. MAR-cleared content.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":189,"textRun":{"content":"ACR symposium (Nov 17 morning): 'Immune-related AE management in advanced NSCLC immunotherapy.' Two speakers, focus on rheumatology referral pathways and corticosteroid-sparing protocols.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":30,"textRun":{"content":"CI and MSL coverage strategy\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":277,"textRun":{"content":"ASCO coverage: Jordan + 2 analysts onsite for embargoed abstract pre-read. CI brief turnaround target: 24-48 hours from embargo lift for any data event with HR < 0.85. Real-time competitive intelligence to executive leadership via Slack with EOD briefings for major sessions.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":138,"textRun":{"content":"ESMO coverage: similar coverage model, MSLs in European territories engaging KOLs in real-time. CI focus on European HTA-impactful data.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":154,"textRun":{"content":"Quarterly briefing cadence: CI team briefs commercial leadership monthly on competitive intelligence, with deeper dives quarterly post-major congresses.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":24,"textRun":{"content":"Post-congress activity\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":197,"textRun":{"content":"Post-ASCO: KOL roundtable virtual call (June 18) to align messaging on the 5-year data. Post-congress brief to commercial team by Friday June 12. MAR-cleared talk track refresh by Friday June 19.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":164,"textRun":{"content":"Post-ESMO: Internal European post-meeting summit (September 22) to coordinate the regional MSL strategy. Symposium recap brief to commercial team by September 25.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":7,"textRun":{"content":"Risks\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":139,"textRun":{"content":"Competitor abstracts at ASCO/ESMO that materially change the competitive positioning. Tracked in the Competitor Monitoring Tracker (1N5).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":131,"textRun":{"content":"Embargo violations: tightly controlled internal access to abstract text pre-embargo. No external commentary until embargo lifted.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":154,"textRun":{"content":"MAR clearance delays for post-congress talk track refresh. Standard 14-day MAR cycle; congress-driven priority requests routed through expedited review.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":18,"textRun":{"content":"Cross-references\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":101,"textRun":{"content":"ASCO 2026 Readout (1L9…), Competitor Monitoring Tracker (1N5…), KOL Advisory Board Apr 2026 (1M2…).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}}]},"documentStyle":{"pageNumberStart":1,"marginTop":{"magnitude":72,"unit":"PT"},"marginBottom":{"magnitude":72,"unit":"PT"},"marginLeft":{"magnitude":72,"unit":"PT"},"marginRight":{"magnitude":72,"unit":"PT"},"pageSize":{"height":{"magnitude":792,"unit":"PT"},"width":{"magnitude":612,"unit":"PT"}}},"namedStyles":{"styles":[{"namedStyleType":"NORMAL_TEXT","textStyle":{"fontSize":{"magnitude":11,"unit":"PT"}}},{"namedStyleType":"TITLE","textStyle":{"fontSize":{"magnitude":26,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_1","textStyle":{"fontSize":{"magnitude":20,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_2","textStyle":{"fontSize":{"magnitude":16,"unit":"PT"},"bold":true}}]},"lists":{},"inlineObjects":{},"headers":{},"footers":{},"footnotes":{},"suggestionsViewMode":"DEFAULT_FOR_CURRENT_ACCESS"}